Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies

  Compugen Announces Collaboration and License Agreement with Bayer for
  Antibody-Based Cancer Immunotherapies

         Compugen to hold 2^nd Quarter Conference Call August 7, 2013

Business Wire

TEL AVIV, Israel -- August 5, 2013

Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a collaboration
and license agreement for the research, development, and commercialization of
antibody-based therapeutics for cancer immunotherapy against two novel
Compugen discovered immune checkpoint regulators. Under the terms of the
agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a
preclinical research program. Subsequently, Bayer will have full control over
further development and have worldwide commercialization rights for potential
cancer therapeutics.

Under the agreement Compugen will receive an upfront payment of USD 10
million, and is eligible to receive over USD 500 million in potential
milestone payments for both programs, not including milestone payments of up
to USD 30 million associated with preclinical activities. Additionally,
Compugen is also eligible to receive mid to high single digit royalties on
global net sales of any resulting products under the collaboration.

“Bayer is committed to translating the science of cancer research into
effective therapies helping people affected by cancer live longer and improve
their quality of life,” said Prof. Andreas Busch, Member of the Bayer
HealthCare Executive Committee and Head of Global Drug Discovery.
“Antibody-based immunotherapies are promising approaches in oncology which can
stimulate the body’s own immune cells to fight cancer cells. Immunotherapy is
one of our focus areas in oncology research. We are looking forward to
expanding our portfolio in this area through partnering with Compugen.”

Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, “We are very
excited to initiate this collaboration with Bayer, a leading global life
science company with a broadening oncology franchise, for the development of
antibody-based cancer immunotherapies against these two promising novel immune
checkpoint targets. In addition, we believe that the prediction and validation
of these two targets, through the use of our broadly applicable predictive
discovery infrastructure, provides additional validation for our long-term
commitment to establishing this unique capability".

The immunotherapy approach aims at combatting cancer by stimulating the body's
own immune cells. The tumor and its environment suppress the ability of cancer
patients to develop an effective anti-tumor immune response and in this way
protect both tumor growth and survival. Compugen has discovered two novel
immune checkpoint regulators that potentially play a key role in
immunosuppression. Researchers at Compugen are developing specific therapeutic
antibodies that are geared to block the immunosuppressive function of these
targets and to reactivate the patient's anti-tumor immune response in order to
fight cancer.

About Cancer Immunotherapy

Latest cancer immunotherapies have demonstrated impressive clinical benefit,
even for end-stage patients with difficult-to-treat tumors such as metastatic
melanoma and non-small cell lung cancer. Unlike conventional cancer therapies,
which act by directly targeting the cancer cells, resulting often in only
transient clinical responses as cancer cells become resistant, clinical
responses to cancer immunotherapy tend to be durable, sometimes resulting in
dramatic long term survival and absence of resistance or recurrences.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins
and monoclonal antibodies to address important unmet needs in the fields of
immunology and oncology.The Company utilizes a broad and continuously growing
integrated infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and other
computational biology capabilities for thein silico(by computer) prediction
and selection of product candidates, which are then advanced in its Pipeline
Program. The Company's business model includes collaborations covering the
further development and commercialization of selected product candidates from
its Pipeline Program and various forms of research and discovery agreements,
in both cases providing Compugen with potential milestone payments and
royalties on product sales or other forms of revenue sharing. In 2012,
Compugen established operations in California for the development of oncology
and immunology monoclonal antibody therapeutic candidates against Compugen
drug targets. For additional information, please visit Compugen's corporate
website at

On August 2, 2013 Compugen filed Form-6K with its financial statements for the
six months ended June 30, 2013 and will host a public conference call at 10:00
AM ET on Wednesday, August 7, 2013 to discuss these results and any questions
with respect to this press release. Further information regarding the
conference call is provided in a separate press release issued today and on
our website.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the
world’s leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines the global
activities of the Animal Health, Consumer Care, Medical Care and
Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop,
manufacture and market products that will improve human and animal health
worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec
31, 2012) and is represented in more than 100 countries. More information at

This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements, which
include statements related to the potential development and commercialization
of antibody-based cancer immunotherapies against the Compugen-discovered
immune checkpoint targets, potential milestone and royalty payments, and that
the collaboration validates Compugen’s predictive discovery infrastructure,
include words such as “may,” “expects,” “anticipates,” “potential,”
“believes,” and “intends,” and describe opinions about future events. These
forward-looking statements involve known and unknown risks and uncertainties
that may cause the actual results, performance or achievements of Compugen to
be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of these risks
and other factors are discussed in the "Risk Factors" section of Compugen’s
Annual Report on Form 20-F for the year ended December 31, 2012 as filed with
the Securities and Exchange Commission. In addition, any forward-looking
statements represent Compugen’s views only as of the date of this release and
should not be relied upon as representing its views as of any subsequent date.
Compugen does not assume any obligation to update any forward-looking
statements unless required by law.


Compugen Ltd.
Tsipi Haitovsky, Global Media Liaison
Press spacebar to pause and continue. Press esc to stop.